del Carpio OL

Language: Spanish
References: 16
Page: 430-433
PDF size: 182.13 Kb.

ABSTRACT

Persistent COVID is defined as the persistence of COVID-19 symptoms 4 weeks after an acute illness, according to the most recent Centers for Disease Control and Prevention definition. It is estimated that 65 million people are affected by this entity, although other figures speak of 200 million affected. According to global statistics, it is estimated that 1 in 10 COVID-19 patients will develop the chronic form called persistent COVID, and the prevalence varies from 7.5 to 14% according to the various European and North American series. Unfortunately in Latin America there are no reliable statistics.

REFERENCES

1. Department of Health and Human Services, Office of theAssistant Secretary for Health. 2022. National ResearchAction Plan on Long COVID, 200 Independence Ave SW,Washington, DC 20201. DOI: 10.1037/e304752003-001

2. The Lancet. Long COVID: 3 years in. Lancet 2023; 401(10379): 795. doi: 10.1016/S0140-6736(23)00493-2

3. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID:major findings, mechanisms and recommendations. NatRev Microbiol 2023; 21 (3): 133-146. doi: 10.1038/s41579-022-00846-2. Erratum in: Nat Rev Microbiol 2023.

4. Del Carpio-Orantes L, Aguilar-Silva A. [Commentary]Long COVID, linking etiopathogenic theories. Qeios 2023.doi:10.32388/A7TYBN

5. Kell DB, Laubscher GJ, Pretorius E. A central role for amyloidfibrin microclots in long COVID/PASC: origins and therapeuticimplications. Biochem J 2022; 479 (4): 537-559. doi:10.1042/BCJ20220016

6. Giannos P, Prokopidis K. Gut dysbiosis and long COVID-19:Feeling gutted. J Med Virol 2022; 94 (7): 2917-2918. doi:10.1002/jmv.27684

7. Badran BW, Huffman SM, Dancy M, Austelle CW, et al. Apilot randomized controlled trial of supervised, at-home,self-administered transcutaneous auricular vagus nervestimulation (taVNS) to manage long COVID symptoms.Bioelectron Med 2022; 8 (1): 13. doi: 10.1186/s42234-022-00094-y

8. Ceban F, Leber A, Jawad MY, Yu M, et al. Registered clinicaltrials investigating treatment of long COVID: a scopingreview and recommendations for research. Infect Dis 2022;54 (7): 467-477. doi: 10.1080/23744235.2022.2043560

9. Besnier F, Bérubé B, Malo J, Gagnon C, et al. Cardiopulmonaryrehabilitation in long-COVID-19 patients withpersistent breathlessness and fatigue: The COVID-RehabStudy. Int J Environ Res Public Health 2022; 19 (7): 4133.doi: 10.3390/ijerph19074133

10. Del Carpio-Orantes L, García-Méndez S, Aguilar-Silva A, etal., Manifestaciones osteomusculares y autoinmunes delCOVID persistente en México, Reumatología Clínica 2023;19. https://doi.org/10.1016/j.reuma.2023.06.003

11. Bello-Chavolla OY, Fermin-Martinez CA, Fernandez-ChirinoL, et-al. Nationally representative prevalence and determinantsof post-acute sequelae of SARS-CoV-2 infection(Long COVID) amongst Mexican adults in 2022. MedRxiv2023. doi: https://doi.org/10.1101/2023.07.10.23292475

12. Halabe-Cherem J, Robledo-Aburto Z, Fajardo-Dolci G.Síndrome Post COVID. 1a ed. México: Panamericana, 2023.

13. Torres-Ruiz J, Lomelín-Gascón J, Lira Luna J, et al. Novelclinical and immunological features associated with persistentpost-acute sequelae of COVID-19 after six monthsof follow-up: a pilot study. Infect Dis (Lond) 2023; 55 (4):243-254. doi: 10.1080/23744235.2022.2158217

14. Del Carpio-Orantes L, Aguilar-Silva A. Teorías del long COVIDentrelazadas para explicar su etiopatogenia [Intertwinedlong COVID theories to explain its etiopathogenesis]. RevMed Inst Mex Seguro Soc 2023; 61 (3): 256-257.

15. Del Carpio-Orantes L. Etiopathogenic theories about longCOVID. World J Virol 2023; 12 (3): 204-208. doi: 10.5501/wjv.v12.i3.204

16. Olivares-Martínez E, Hernadez-Ramirez DF, Nuñez-AlvarezCA, et-al. Polymerized type I collagen down-regulatesSTAT-1 phosphorylation through engagement to LAIR-1 inM1-macrophages avoiding long COVID. MedRxiv 2023. doi:https://doi.org/10.1101/2023.07.01.23292108